Pfizer partners with BioNTech to develop vaccine for Influenza for $425M
Shots:
- Pfizer is planning to pay $120M upfront along with $305M milestone payment
- BioNTech will also receive double-digit royalties post sales whereas- Pfizer acquires small stakes in BioNTech as part of upfront payment
- Pfizer plans to do further trials and commercialization of vaccines post completion of the first clinical study by BioNTech
Ref: Reuters | Image: Twitter
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com